Adverse effects of class I antiarrhythmic drugs.
Class I antiarrhythmic drugs are characterised by their ability to block the fast inward sodium current in cardiac muscle tissue. However, at the same time, they can be responsible for various effects involving other organs and systems. Although some of these effects can be helpful in specific situations, most of them, such as their pro-arrhythmic propensity, are deleterious. Some of the adverse effects of class I antiarrhythmic drugs are directly linked to sodium-channel blockade (conduction disorders haemodynamic perturbations, and digestive and neurological effects), while others are linked to other specific pharmacological properties (e.g. atropinic, or alpha- or beta-adrenergic blockade) or to nonspecific properties (idiosyncratic hypersensitivity, and haematological, dermatological or hepatic reactions). Other adverse effects are associated with complex interactions between class I antiarrhythmics and individual predisposing factors, trigger mechanisms and physiological factors (including concomitant drug treatment). These numerous variations and interactions within a specific environment and underlying disorder might be of pharmacological or/and pharmacokinetic origin, making analysis of the true liability of the class I drugs very difficult when adverse effects occur.
Caron
J
J
Centre Régional de Pharmacovigilance, Service de Pharmacologie Hospitalière, Faculté de Médecine, Université Droit et Santé, Lille, France.
Libersa
C
C
D000772:Anesthesia, Local / Q000009:adverse effects*; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects* / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use; D001341:Autonomic Nervous System / Q000187:drug effects*; D004347:Drug Interactions; D004562:Electrocardiography / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D015221:Potassium Channels / Q000187:drug effects*; D026941:Sodium Channel Blockers; D013329:Structure-Activity Relationship
D000889:Anti-Arrhythmia Agents; D015221:Potassium Channels; D026941:Sodium Channel Blockers